- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Prestige Will License Trastuzumab Biosimilar to Cipla
Under terms of the agreement, Cipla will have exclusive rights to distribute and market Prestige’s trastuzumab biosimilar (HD201) in selected emerging markets.
Prestige Biopharma, a Singapore-based biopharmaceutical company, recently announced that it has entered into a licensing agreement with Cipla Limited. Under terms of the agreement, Cipla will have exclusive rights to distribute and market Prestige’s trastuzumab biosimilar (HD201) in selected emerging markets.
The biosimilar, referencing Roche’s Herceptin, is currently being investigated in a phase 3 study for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Prestige plans to submit the proposed biosimilar for regulatory approval with the European Medicines Agency and with the FDA in 2019.
“We are very pleased to partner with Cipla to commercialize our lead biosimilar program in selected emerging markets. With this partnership, we made another important step towards a broad global availability of our trastuzumab biosimilar product,” said Lisa Park, CEO of Prestige, in a statement.
The agreement will focus on leveraging Cipla’s strong local presence as well as sales and marketing capabilities within the local markets. Through the agreement, Prestige will be responsible for the development, product registration, and commercial supply of the biosimilar, while Cipla will be responsible for the marketing and commercialization.
“Cipla has always stood for access to life-saving medicines, and through this partnership, we take this key drug to more countries and patients around the world. We will continue to focus on capitalizing on our strengths to ensure high-quality medicines to patients in keeping with our purpose of ‘Caring for Life,’” said Umang Vohra, managing director and global CEO of Cipla.
Other products currently being developed in Prestige’s pipeline include HD204, a potential bevacizumab biosimilar currently undergoing phase 1 and 3 trials, and PBP1502, a potential adalimumab biosimilar currently in a phase 1 trial. Potential biosimilars in preclinical development include denosumab, aflibercept, eculizumab, and ipilimumab molecules.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
